{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:42:50Z","timestamp":1791085370739,"version":"4.1.0"},"reference-count":153,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.pharmthera.2012.07.004","type":"journal-article","created":{"date-parts":[[2012,7,14]],"date-time":"2012-07-14T07:20:07Z","timestamp":1342250407000},"page":"56-68","source":"Crossref","is-referenced-by-count":66,"title":["The application and biology of immunomodulatory drugs (IMiDs) in cancer"],"prefix":"10.1016","volume":"136","author":[{"given":"Beiqing","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.pharmthera.2012.07.004_bb0510","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1182\/blood-2008-08-175778","article-title":"Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. [Clinical Trial, Phase II]","volume":"113","author":"Ades","year":"2009","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.pharmthera.2012.07.004_bb0515","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.2007.13.9709","article-title":"Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia","volume":"26","author":"Andritsos","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.pharmthera.2012.07.004_bb0520","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.pharmthera.2012.07.004_bb0525","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.pharmthera.2012.07.004_bb0530","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/ajh.22114","article-title":"Inflammation, TNFalpha and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia","volume":"86","author":"Aue","year":"2011","journal-title":"Am J Hematol"},{"issue":"13","key":"10.1016\/j.pharmthera.2012.07.004_bb0535","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2011-03-339077","article-title":"Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia","volume":"118","author":"Badoux","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.pharmthera.2012.07.004_bb0540","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2009.25.6081","article-title":"Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences","volume":"28","author":"Barlogie","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.pharmthera.2012.07.004_bb0545","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2008-03-145235","article-title":"Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.pharmthera.2012.07.004_bb0550","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pharmthera.2012.07.004_bb0555","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/leu.2010.254","article-title":"A phase-2 trial of low-dose pomalidomide in myelofibrosis","volume":"25","author":"Begna","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.pharmthera.2012.07.004_bb0560","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2010.01524.x","article-title":"Addition of thalidomide to oral melphalan\/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group","volume":"86","author":"Beksac","year":"2011","journal-title":"Eur J Haematol"},{"issue":"14","key":"10.1016\/j.pharmthera.2012.07.004_bb0565","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJM197910043011402","article-title":"The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia","volume":"301","author":"Bergsagel","year":"1979","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.pharmthera.2012.07.004_bb0570","doi-asserted-by":"crossref","first-page":"e704","DOI":"10.1200\/JCO.2010.30.0038","article-title":"Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone","volume":"28","author":"Bibas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.pharmthera.2012.07.004_bb0575","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1200\/JCO.2010.30.3339","article-title":"Dose escalation of lenalidomide in relapsed or refractory acute leukemias. [Clinical Trial, Phase I Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]","volume":"28","author":"Blum","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.pharmthera.2012.07.004_bb0580","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/sj.leu.2404661","article-title":"Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield","volume":"21","author":"Breitkreutz","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.pharmthera.2012.07.004_bb0585","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00277-010-0967-4","article-title":"Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed\/refractory multiple myeloma (MM): a single-centre experience","volume":"90","author":"Caravita","year":"2011","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.pharmthera.2012.07.004_bb0590","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/leu.2011.131","article-title":"Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy","volume":"25","author":"Cavallo","year":"2011","journal-title":"Leukemia"},{"issue":"9758","key":"10.1016\/j.pharmthera.2012.07.004_bb0595","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.pharmthera.2012.07.004_bb0600","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/cncr.25748","article-title":"Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response","volume":"117","author":"Chanan-Khan","year":"2010","journal-title":"Cancer"},{"issue":"34","key":"10.1016\/j.pharmthera.2012.07.004_bb0605","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.pharmthera.2012.07.004_bb0610","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood-2005-02-0669","article-title":"Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)","volume":"106","author":"Chanan-Khan","year":"2005","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.pharmthera.2012.07.004_bb0615","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1200\/JCO.2008.18.2857","article-title":"Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.pharmthera.2012.07.004_bb0620","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2010.29.8133","article-title":"Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia","volume":"29","author":"Chen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.pharmthera.2012.07.004_bb0625","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2141.2011.08781.x","article-title":"The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin","volume":"154","author":"Czuczman","year":"2011","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.pharmthera.2012.07.004_bb0630","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/sj.leu.2403058","article-title":"Thalidomide therapy induces response in relapsed mantle cell lymphoma","volume":"17","author":"Damaj","year":"2003","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.pharmthera.2012.07.004_bb0635","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.pharmthera.2012.07.004_bb0640","first-page":"800","article-title":"Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood","volume":"85","author":"Di Raimondo","year":"2000","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.pharmthera.2012.07.004_bb0645","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1002\/cncr.25139","article-title":"The efficacy and safety of lenalidomide plus dexamethasone in relapsed and\/or refractory multiple myeloma patients with impaired renal function","volume":"116","author":"Dimopoulos","year":"2010","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.pharmthera.2012.07.004_bb0650","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.pharmthera.2012.07.004_bb0655","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.leu.2403710","article-title":"Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide","volume":"19","author":"Dogan","year":"2005","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.pharmthera.2012.07.004_bb0660","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/cncr.24686","article-title":"Results of a multicenter, randomized, double-blind phase 2\/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma","volume":"116","author":"Eisen","year":"2010","journal-title":"Cancer"},{"issue":"9594","key":"10.1016\/j.pharmthera.2012.07.004_bb0665","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201306): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.pharmthera.2012.07.004_bb0670","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","article-title":"A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma","volume":"118","author":"Fehniger","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pharmthera.2012.07.004_bb0675","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1182\/blood-2010-07-297143","article-title":"A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. [Clinical Trial, Phase II Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]","volume":"117","author":"Fehniger","year":"2011","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.pharmthera.2012.07.004_bb0680","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.pharmthera.2012.07.004_bb0685","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"111","author":"Ferrajoli","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.pharmthera.2012.07.004_bb0690","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ajh.21777","article-title":"Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma","volume":"85","author":"Gay","year":"2010","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.pharmthera.2012.07.004_bb0695","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2141.2010.08534.x","article-title":"Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma","volume":"152","author":"Ghosh","year":"2011","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.pharmthera.2012.07.004_bb0700","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/leu.2009.98","article-title":"Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide\/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia","volume":"23","author":"Giannopoulos","year":"2009","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.pharmthera.2012.07.004_bb0705","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1002\/cncr.24576","article-title":"Results of a multicenter, randomized, double-blind, dose-evaluating phase 2\/3 study of lenalidomide in the treatment of metastatic malignant melanoma","volume":"115","author":"Glaspy","year":"2009","journal-title":"Cancer"},{"issue":"25","key":"10.1016\/j.pharmthera.2012.07.004_bb0710","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1200\/JCO.2010.32.4962","article-title":"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein","volume":"29","author":"Hofmeister","year":"2011","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.pharmthera.2012.07.004_bb0715","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.pharmthera.2012.07.004_bb0720","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejca.2010.09.002","article-title":"A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer","volume":"47","author":"Infante","year":"2011","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.pharmthera.2012.07.004_bb0725","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00018-010-0619-9","article-title":"Teratogenic effects of thalidomide: molecular mechanisms","volume":"68","author":"Ito","year":"2011","journal-title":"Cell Mol Life Sci"},{"issue":"5971","key":"10.1016\/j.pharmthera.2012.07.004_bb0730","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.pharmthera.2012.07.004_bb0735","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2010-12-325589","article-title":"Comparison of thalidomide and lenalidomide as therapy for myelofibrosis","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmthera.2012.07.004_bb0740","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2011-02-334755","article-title":"Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1\/2 Multiple Myeloma Research Consortium trial","volume":"118","author":"Jakubowiak","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmthera.2012.07.004_bb0745","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2010.313","article-title":"Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and\/or transplant ineligible patients with multiple myeloma: a meta-analysis","volume":"25","author":"Kapoor","year":"2011","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.pharmthera.2012.07.004_bb0750","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","article-title":"Antitumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma","volume":"104","author":"Kaufmann","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.pharmthera.2012.07.004_bb0755","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2011-04-348292","article-title":"Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial","volume":"118","author":"Kneppers","year":"2011","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.pharmthera.2012.07.004_bb0760","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1182\/blood-2008-10-184135","article-title":"Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)","volume":"113","author":"Knop","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.pharmthera.2012.07.004_bb0765","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1182\/blood-2004-03-0828","article-title":"Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis","volume":"105","author":"Koh","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.pharmthera.2012.07.004_bb0770","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.2011.044271","article-title":"Thalidomide versus dexamethasone for the treatment of relapsed and\/or refractory multiple myeloma: results from OPTIMUM, a randomized trial","volume":"97","author":"Kropff","year":"2011","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.pharmthera.2012.07.004_bb0775","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","article-title":"Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma","volume":"21","author":"Kumar","year":"2007","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.pharmthera.2012.07.004_bb0780","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/leu.2010.116","article-title":"Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study","volume":"24","author":"Kumar","year":"2010","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.pharmthera.2012.07.004_bb0785","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/ajh.22053","article-title":"Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial","volume":"86","author":"Kumar","year":"2011","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.pharmthera.2012.07.004_bb0790","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmthera.2012.07.004_bb0795","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.3816\/CLM.2009.n.053","article-title":"Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide. [Case Reports Research Support, Non-U.S. Gov't]","volume":"9","author":"Kurtin","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"11","key":"10.1016\/j.pharmthera.2012.07.004_bb0800","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1182\/blood-2011-04-348896","article-title":"Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease","volume":"118","author":"Lacy","year":"2011","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.pharmthera.2012.07.004_bb0805","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.pharmthera.2012.07.004_bb0810","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/leu.2010.190","article-title":"Pomalidomide (CC4047) plus low dose dexamethasone (Pom\/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)","volume":"24","author":"Lacy","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2012.07.004_bb0815","series-title":"blood (ASH Annual Meeting Abstract), 118, Abstract 3963","article-title":"Pomalidomide and dexamethasone in relapsed myeloma: results of 225 patients treated in five cohorts over three years","author":"Lacy","year":"2011"},{"issue":"23","key":"10.1016\/j.pharmthera.2012.07.004_bb0820","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMc1111010","article-title":"Myeloma and second primary cancers","volume":"365","author":"Landgren","year":"2011","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.pharmthera.2012.07.004_bb0825","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1182\/blood-2008-01-133108","article-title":"Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells","volume":"112","author":"Lapalombella","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmthera.2012.07.004_bb0830","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pharmthera.2012.07.004_bb0835","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1200\/JCO.2005.03.7309","article-title":"Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.pharmthera.2012.07.004_bb0840","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.1200\/JCO.2009.21.9733","article-title":"Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer","volume":"27","author":"Lee","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2012.07.004_bb0845","series-title":"Blood (ASH Annual Meeting Abstract), 118, Abstract 812","article-title":"High response rates to pomalidomide and dexamethasone in patients with refractory myeloma, final analysis of IFM 2009\u201302","author":"Leleu","year":"2011"},{"issue":"20","key":"10.1016\/j.pharmthera.2012.07.004_bb0850","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1182\/blood-2011-12-395715","article-title":"Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1\/2 open-label, dose escalation study","volume":"119","author":"Lentzsch","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pharmthera.2012.07.004_bb0855","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/CCO.0b013e32834bcc2a","article-title":"Therapy-related myeloid neoplasms","volume":"23","author":"Leone","year":"2011","journal-title":"Curr Opin Oncol"},{"issue":"19","key":"10.1016\/j.pharmthera.2012.07.004_bb0860","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1182\/blood-2010-10-314278","article-title":"IMiD immunomodulatory compounds block C\/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.pharmthera.2012.07.004_bb0865","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharmthera.2012.07.004_bb0010","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes. [Clinical Trial Research Support, U.S. Gov't, P.H.S.]","volume":"352","author":"List","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.07.004_bb0020","series-title":"Blood (ASH Annual Meeting Abstract), 118, Abstract 1840","article-title":"IMiD\u00ae Immunomodulatory Drugs Lenalidomide and Pomalidomide Inhibit the Maturation of Megakaryocytes by Suppressing the Expression of GATA1","author":"Liu","year":"2011"},{"issue":"6","key":"10.1016\/j.pharmthera.2012.07.004_bb0025","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmthera.2012.07.004_bb0030","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","article-title":"Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response","volume":"154","author":"Lopez-Girona","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharmthera.2012.07.004_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.pharmthera.2012.07.004_bb0040","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3324\/haematol.2009.020586","article-title":"Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma","volume":"95","author":"Ludwig","year":"2010","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.pharmthera.2012.07.004_bb0045","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","article-title":"Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma","volume":"113","author":"Ludwig","year":"2009","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.pharmthera.2012.07.004_bb0050","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2011-05-355743","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)","volume":"118","author":"Mailankody","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.pharmthera.2012.07.004_bb0055","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.bbmt.2008.04.008","article-title":"Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma","volume":"14","author":"Mark","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"10.1016\/j.pharmthera.2012.07.004_bb0060","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","volume":"28","author":"Mateos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.pharmthera.2012.07.004_bb0085","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/sj.leu.2405035","article-title":"Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients","volume":"22","author":"Mazumder","year":"2008","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.pharmthera.2012.07.004_bb0090","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pharmthera.2012.07.004_bb0095","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.21598","article-title":"Phase1\/-2 study of Pomalidomide in myelofibrosis","volume":"85","author":"Mesa","year":"2010","journal-title":"Am J Hematol"},{"issue":"22","key":"10.1016\/j.pharmthera.2012.07.004_bb0100","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1182\/blood-2010-05-287417","article-title":"Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903","volume":"116","author":"Mesa","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmthera.2012.07.004_bb0105","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/bmt.2010.118","article-title":"Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide","volume":"46","author":"Micallef","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.pharmthera.2012.07.004_bb0110","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3324\/haematol.2010.039669","article-title":"Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities","volume":"96","author":"Mollgard","year":"2011","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.pharmthera.2012.07.004_bb0115","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1182\/blood-2011-05-353995","article-title":"Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment","volume":"118","author":"Morabito","year":"2011","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.pharmthera.2012.07.004_bb0120","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.pharmthera.2012.07.004_bb0125","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2011-02-338665","article-title":"Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation","volume":"118","author":"Morgan","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2012.07.004_bb0130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2012.07.004_bb0135","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1172\/JCI32322","article-title":"Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells","volume":"118","author":"Moutouh-de Parseval","year":"2008","journal-title":"J Clin Invest"},{"issue":"31","key":"10.1016\/j.pharmthera.2012.07.004_bb0140","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1200\/JCO.2007.14.2141","article-title":"Tumor lysis syndrome\/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia","volume":"25","author":"Moutouh-de Parseval","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.pharmthera.2012.07.004_bb0145","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1182\/blood-2006-11-059378","article-title":"Cyclin D-Cdk4 is regulated by GATA-1 and required for megakaryocyte growth and polyploidization","volume":"109","author":"Muntean","year":"2007","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.pharmthera.2012.07.004_bb0150","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","article-title":"Superior results of Total Therapy 3 (2003\u201333) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006\u201366 with VRD maintenance","volume":"115","author":"Nair","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.pharmthera.2012.07.004_bb0155","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/leu.2011.165","article-title":"Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study","volume":"25","author":"Nowakowski","year":"2011","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.pharmthera.2012.07.004_bb0160","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-0609.2010.01473.x","article-title":"Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion. [Clinical Trial, Phase II Multicenter Study Research Support, Non-U.S. Gov't]","volume":"85","author":"Oliva","year":"2010","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.pharmthera.2012.07.004_bb0175","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.clml.2011.11.003","article-title":"Observations of Second Primary Malignancy in Patients With Multiple Myeloma","volume":"12","author":"Ormerod","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.pharmthera.2012.07.004_bb0180","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1182\/blood-2009-05-221077","article-title":"Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia","volume":"115","author":"Pal","year":"2010","journal-title":"Blood"},{"issue":"9513","key":"10.1016\/j.pharmthera.2012.07.004_bb0185","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.pharmthera.2012.07.004_bb0190","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.pharmthera.2012.07.004_bb0195","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.pharmthera.2012.07.004_bb0200","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1200\/JCO.2007.12.3463","article-title":"Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA\u2013Italian Multiple Myeloma Network","volume":"25","author":"Palumbo","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.pharmthera.2012.07.004_bb0205","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.2009.22.7561","article-title":"Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.pharmthera.2012.07.004_bb0210","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.pharmthera.2012.07.004_bb0215","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/leu.2010.58","article-title":"Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed\/refractory multiple myeloma","volume":"24","author":"Palumbo","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.pharmthera.2012.07.004_bb0220","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"27","key":"10.1016\/j.pharmthera.2012.07.004_bb0225","doi-asserted-by":"crossref","first-page":"11406","DOI":"10.1073\/pnas.0610477104","article-title":"Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients","volume":"104","author":"Pellagatti","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"10.1016\/j.pharmthera.2012.07.004_bb0230","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.2007.11.8109","article-title":"Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00\u201301","volume":"25","author":"Pujol","year":"2007","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.pharmthera.2012.07.004_bb0235","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1200\/JCO.2009.22.6548","article-title":"Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis","volume":"27","author":"Quintas-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.pharmthera.2012.07.004_bb0240","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.pharmthera.2012.07.004_bb0245","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.leu.2401336","article-title":"Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma","volume":"13","author":"Rajkumar","year":"1999","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.pharmthera.2012.07.004_bb0250","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.pharmthera.2012.07.004_bb0255","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl. 8","key":"10.1016\/j.pharmthera.2012.07.004_bb0260","first-page":"ECR44","article-title":"Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone","volume":"91","author":"Ramasamy","year":"2006","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.pharmthera.2012.07.004_bb0265","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood.V98.4.958","article-title":"Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes","volume":"98","author":"Raza","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2012.07.004_bb0270","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood-2007-01-068833","article-title":"Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q","volume":"111","author":"Raza","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmthera.2012.07.004_bb0275","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2008-12-196238","article-title":"Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma","volume":"114","author":"Richardson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2012.07.004_bb0280","series-title":"Blood (ASH Annual Meeting Abstract), 118, Abstract 634","author":"Richardson","year":"2011"},{"issue":"34","key":"10.1016\/j.pharmthera.2012.07.004_bb0285","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1200\/JCO.2009.22.2679","article-title":"Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed\/refractory multiple myeloma","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.pharmthera.2012.07.004_bb0290","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.pharmthera.2012.07.004_bb0295","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1200\/JCO.2011.34.7252","article-title":"Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy","volume":"29","author":"Rubenstein","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.pharmthera.2012.07.004_bb0305","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. [Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmthera.2012.07.004_bb0300","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3816\/CLML.2010.n.120","article-title":"Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone","volume":"11","author":"San-Miguel","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"16","key":"10.1016\/j.pharmthera.2012.07.004_bb0330","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1200\/JCO.2004.10.052","article-title":"Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma","volume":"22","author":"Schey","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.pharmthera.2012.07.004_bb0335","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2141.2010.08250.x","article-title":"The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed\/refractory myeloma patients; a phase I\/II study","volume":"150","author":"Schey","year":"2010","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.pharmthera.2012.07.004_bb0340","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood-2011-02-337303","article-title":"A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. [Clinical Trial, Phase II Research Support, N.I.H., Extramural]","volume":"118","author":"Sekeres","year":"2011","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.pharmthera.2012.07.004_bb0350","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1200\/JCO.2009.26.0745","article-title":"Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. [Clinical Trial, Phase I Multicenter Study Research Support, N.I.H., Extramural]","volume":"28","author":"Sekeres","year":"2010","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.pharmthera.2012.07.004_bb0365","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1200\/JCO.2007.15.5770","article-title":"Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. [Clinical Trial, Phase II Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]","volume":"26","author":"Sekeres","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.pharmthera.2012.07.004_bb0380","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ajh.21891","article-title":"Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. [Case Reports Clinical Trial, Phase I Multicenter Study Research Support, N.I.H., Extramural]","volume":"86","author":"Sekeres","year":"2011","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.pharmthera.2012.07.004_bb0400","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/10428190903406806","article-title":"Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics","volume":"51","author":"Sher","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pharmthera.2012.07.004_bb0405","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/cpt196563303","article-title":"Thalidomide in the Treatment of Lepra Reactions","volume":"6","author":"Sheskin","year":"1965","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.pharmthera.2012.07.004_bb0410","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2011.29","article-title":"Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma","volume":"25","author":"Short","year":"2011","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.pharmthera.2012.07.004_bb0415","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2141.2011.08979.x","article-title":"Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents","volume":"156","author":"Sibon","year":"2012","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.pharmthera.2012.07.004_bb0420","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.pharmthera.2012.07.004_bb0425","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1600-0609.2009.01257.x","article-title":"Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma","volume":"82","author":"Stadtmauer","year":"2009","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.pharmthera.2012.07.004_bb0430","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2141.2008.07013.x","article-title":"Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation","volume":"141","author":"Streetly","year":"2008","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.pharmthera.2012.07.004_bb0435","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1182\/blood-2006-02-004572","article-title":"Lenalidomide therapy in myelofibrosis with myeloid metaplasia","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.pharmthera.2012.07.004_bb0440","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1038\/sj.leu.2404711","article-title":"Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions","volume":"21","author":"Tefferi","year":"2007","journal-title":"Leukemia"},{"issue":"27","key":"10.1016\/j.pharmthera.2012.07.004_bb0445","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2008.21.7356","article-title":"Pomalidomide is active in the treatment of anemia associated with myelofibrosis","volume":"27","author":"Tefferi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.pharmthera.2012.07.004_bb0450","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1056\/NEJMoa0912228","article-title":"Persistent malignant stem cells in del(5q) myelodysplasia in remission. [Research Support, Non-U.S. Gov't]","volume":"363","author":"Tehranchi","year":"2010","journal-title":"N Engl J Med"},{"issue":"Suppl. 6","key":"10.1016\/j.pharmthera.2012.07.004_bb0455","first-page":"ECR16","article-title":"Thalidomide induced remission of refractory diffuse large B-Cell Lymphoma post-allogeneic SCT","volume":"91","author":"Tueger","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.pharmthera.2012.07.004_bb0460","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/0008-5472.CAN-06-2317","article-title":"Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells","volume":"67","author":"Verhelle","year":"2007","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.pharmthera.2012.07.004_bb0465","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.pharmthera.2012.07.004_bb0470","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"30","key":"10.1016\/j.pharmthera.2012.07.004_bb0475","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.pharmthera.2012.07.004_bb0480","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.pharmthera.2012.07.004_bb0485","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"issue":"32","key":"10.1016\/j.pharmthera.2012.07.004_bb0490","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.pharmthera.2012.07.004_bb0495","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3324\/haematol.2009.010876","article-title":"Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion","volume":"95","author":"Ximeri","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.pharmthera.2012.07.004_bb0500","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3324\/haematol.2011.051813","article-title":"Salvage treatment with lenalidomide and dexamethasone in relapsed\/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers","volume":"97","author":"Zaja","year":"2012","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.pharmthera.2012.07.004_bb0505","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725812001295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725812001295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T21:04:31Z","timestamp":1714165471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725812001295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":153,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0163725812001295"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2012.07.004","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}